Objective: Although short-term results of off-pump coronary artery bypass grafting are well documented, late postoperative data are still scarce. This report provides an analysis of late postoperative control angiograms.
Methods: 265 patients (231 males, 34 females; mean age: 54 +/- 10) underwent postoperative angiographic control, after an average postoperative period of 4.2 +/- 2.3 years (up to 9 years, a total of 1110 years). A total of 385 distal anastomoses on 258 internal mammary arteries (IMAs) and 127 saphenous vein grafts (SVGs) were evaluated. The primary operation was single bypass in 156 cases (62%), double bypass in 98 (34%), and triple or more bypass in 11 (4%).
Results: Out of 258 IMAs, 241 were patent (93%), while SVG patency was 65% with 82 patent grafts out of 127 (p < 0.0001). The patency in the lateral branches (62%) and right coronary system (64%) were similar. The variables associated with graft occlusion were hypercholesterolemia (p = 0.02), poor left ventricular performance (p = 0.03), reoperation (p = 0.01), target coronary vessel caliber less than 1.5 mm (p < 0.0001), poor native coronary vessel quality (p = 0.0003) and low-grade stenosis (p = 0.02). In the poor left ventricle group, the left ventricular segmental wall motion score was improved (p = 0.004). Consequently, 47 patients underwent secondary revascularization (35 PTCA and 12 CABG). The leading indication was native coronary artery disease progression, frequently in the circumflex system, followed by graft failure. The cases with native vessel disease progression were referred to PTCA/stenting, while those with LAD graft occlusion were treated surgically.
Conclusions: Probably the best candidates for OPCAB are those having target vessels of good caliber and quality, and high-grade stenoses. Postoperative lipid-lowering therapy seems to be prudential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.0886-0440.2005.200451.x | DOI Listing |
Asian Cardiovasc Thorac Ann
January 2025
Departments of Cardiac Surgery, HMC, Doha, Qatar.
Bombay blood (hh blood) is a rare blood group (4 per million), with no expression of the H antigen present in blood group O. Bombay blood patients can only receive Bombay blood, with autodonation used for elective surgery. We present a Bombay patient (haemoglobin 12.
View Article and Find Full Text PDFCirc Cardiovasc Qual Outcomes
January 2025
Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. (N.P.A., A.C.S., M.W.S., M.J.M., T.H., S.A.M.).
Background: The High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome) pathway risk stratifies emergency department patients with possible acute coronary syndrome. This study aims to determine if the High-STEACS hs-cTnT (high-sensitivity cardiac troponin T) pathway can achieve the ≥99% negative predictive value (NPV) safety threshold for 30-day cardiac death or myocardial infarction (CDMI) in a multisite US cohort of patients with and without known coronary artery disease (CAD).
Methods: A secondary analysis of the STOP-CP (High-Sensitivity Cardiac Troponin T [Gen 5 STAT Assay] to Optimize Chest Pain Risk Stratification) cohort, which enrolled adult emergency department patients with possible acute coronary syndrome at 8 US sites (January 25, 2017-September 6, 2018).
Circulation
January 2025
Department of Cardiology, Tokyo Medical University Hachioji Medical Center, Japan (T. Kubo, N.T.).
Background: Limited large-scale, real-world data exist on the prevalence and clinical impact of discordance between fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs).
Methods: The J-PRIDE registry (Clinical Outcomes of Japanese Patients With Coronary Artery Disease Assessed by Resting Indices and Fractional Flow Reserve: A Prospective Multicenter Registry) prospectively enrolled 4304 lesions in 3200 patients from 20 Japanese centers. The lesions were classified into FFR+/NHPR-, FFR-/NHPR+, FFR+/NHPR+, or FFR-/NHPR groups according to cutoff values of 0.
Curr Vasc Pharmacol
January 2025
Cardiology Department, Athens Naval Hospital, Athens, Greece.
Background: Gut microbiota-derived metabolite Trimethylamine-N-oxide (TMAO) is increasingly recognized as a potential novel prognostic biomarker for cardiovascular disease. Our research work aimed to investigate the potential utility of TMAO measurement in patients with STelevation Myocardial Infarction (STEMI).
Methods: We performed a systematic literature search in PubMed from inception to the 1st of February 2024 to identify all studies examining the association between plasma TMAO levels and disease complexity or clinical outcomes in STEMI patients.
Sci Prog
January 2025
Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Objective: Coronary artery disease (CAD) remains a significant global health burden, characterized by the narrowing or blockage of coronary arteries. Treatment decisions are often guided by angiography-based scoring systems, such as the Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) and Gensini scores, although these require invasive procedures. This study explores the potential of electrocardiography (ECG) as a noninvasive diagnostic tool for predicting CAD severity, alongside traditional risk factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!